<DrugInformationSummary id="CDR0000487564"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Bevacizumab works by blocking a protein called VEGF, which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/bevacizumab">Bevacizumab</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000043234">bevacizumab</TerminologyLink><GlossaryLink ref="CDR0000046115">bevacizumab</GlossaryLink><USBrandNames><USBrandName>Alymsys</USBrandName><USBrandName>Avastin</USBrandName><USBrandName>Jobevne</USBrandName><USBrandName>Mvasi</USBrandName><USBrandName>Zirabev</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>beh-vuh-SIH-zoo-mab</TermPronunciation><MediaLink ref="CDR0000707697" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000707696" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=BEVACIZUMAB&amp;pagesize=20&amp;page=1">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Bevacizumab</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&amp;query=BEVACIZUMAB&amp;pagesize=20&amp;page=1">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_8">Bevacizumab is approved to be used alone or with other <GlossaryTermRef href="CDR0000348921" dictionary="Cancer.gov" audience="Patient">drugs</GlossaryTermRef> to treat:</Para><ItemizedList Style="bullet" id="_9"><ListItem><Strong><GlossaryTermRef href="CDR0000444973" dictionary="Cancer.gov" audience="Patient">Cervical cancer</GlossaryTermRef></Strong> that has not gotten better with other treatment, has spread to other parts of the body, or has come back. It is used with <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef> and either <GlossaryTermRef href="CDR0000045230" dictionary="Cancer.gov" audience="Patient">cisplatin</GlossaryTermRef> or <GlossaryTermRef href="CDR0000507692" dictionary="Cancer.gov" audience="Patient">topotecan hydrochloride</GlossaryTermRef>. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000444983" dictionary="Cancer.gov" audience="Patient">Colorectal cancer</GlossaryTermRef></Strong> that has spread to other parts of the body.  It is used:<ItemizedList Style="bullet" id="_12"><ListItem>With fluorouracil as the first or second treatment.</ListItem><ListItem>With  a <GlossaryTermRef href="CDR0000386207" dictionary="Cancer.gov" audience="Patient">fluoropyrimidine</GlossaryTermRef> and either <GlossaryTermRef href="CDR0000635811" dictionary="Cancer.gov" audience="Patient">irinotecan hydrochloride</GlossaryTermRef> or <GlossaryTermRef href="CDR0000045465" dictionary="Cancer.gov" audience="Patient">oxaliplatin</GlossaryTermRef> as the second treatment in patients whose disease has gotten worse after therapy that included bevacizumab.</ListItem></ItemizedList> This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000045698" dictionary="Cancer.gov" audience="Patient">Glioblastoma</GlossaryTermRef></Strong> (a type of brain <GlossaryTermRef href="CDR0000045333" dictionary="Cancer.gov" audience="Patient">cancer</GlossaryTermRef>) that has come back. It is used in adults. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046363" dictionary="Cancer.gov" audience="Patient">Hepatocellular carcinoma</GlossaryTermRef></Strong> (a type of <GlossaryTermRef href="CDR0000044242" dictionary="Cancer.gov" audience="Patient">liver cancer</GlossaryTermRef>) that has spread to other parts of the body or cannot be removed by surgery. It is used with <GlossaryTermRef href="CDR0000781154" dictionary="Cancer.gov" audience="Patient">atezolizumab</GlossaryTermRef> in patients who have not received <GlossaryTermRef href="CDR0000045922" dictionary="Cancer.gov" audience="Patient">systemic therapy</GlossaryTermRef>. This use is approved for the Avastin brand of bevacizumab.</ListItem><ListItem><Strong>Nonsquamous <GlossaryTermRef href="CDR0000045323" dictionary="Cancer.gov" audience="Patient">non-small cell lung cancer</GlossaryTermRef></Strong> that is has spread, cannot be removed by surgery, or has come back. It is used with <GlossaryTermRef href="CDR0000045182" dictionary="Cancer.gov" audience="Patient">carboplatin</GlossaryTermRef> and <GlossaryTermRef href="CDR0000045258" dictionary="Cancer.gov" audience="Patient">paclitaxel</GlossaryTermRef> as the first therapy. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.</ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000046768" dictionary="Cancer.gov" audience="Patient">Ovarian epithelial</GlossaryTermRef>,</Strong> <Strong><GlossaryTermRef href="CDR0000755773" dictionary="Cancer.gov" audience="Patient">fallopian tube</GlossaryTermRef>,</Strong> or <Strong><GlossaryTermRef href="CDR0000386215" dictionary="Cancer.gov" audience="Patient">primary peritoneal cancer</GlossaryTermRef>.</Strong> It is used:<ItemizedList Style="bullet" id="_14"><ListItem>With carboplatin and paclitaxel and then alone in patients with <GlossaryTermRef href="CDR0000045901" dictionary="Cancer.gov" audience="Patient">stage III</GlossaryTermRef>, <GlossaryTermRef href="CDR0000045902" dictionary="Cancer.gov" audience="Patient">stage IV</GlossaryTermRef>, or recurrent cancer. It is given after surgery. This use is approved for the Avastin, Mvasi, and Zirabev brands of bevacizumab.</ListItem><ListItem>With paclitaxel, <GlossaryTermRef href="CDR0000560136" dictionary="Cancer.gov" audience="Patient">doxorubicin hydrochloride liposome</GlossaryTermRef>, or topotecan hydrochloride in patients whose cancer has come back, does not respond to platinum chemotherapy, and has been treated with  up to two types of chemotherapy. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.</ListItem><ListItem>With carboplatin and paclitaxel or carboplatin and <GlossaryTermRef href="CDR0000508951" dictionary="Cancer.gov" audience="Patient">gemcitabine hydrochloride</GlossaryTermRef> and then alone in patients whose cancer responds to platinum chemotherapy and has come back. This use is approved for the Avastin, Mvasi, and Zirabev brands of bevacizumab.</ListItem></ItemizedList> </ListItem><ListItem><Strong><GlossaryTermRef href="CDR0000661352" dictionary="Cancer.gov" audience="Patient">Renal cell carcinoma</GlossaryTermRef></Strong> (a type of kidney cancer) that has spread to other parts of the body. It is used with <GlossaryTermRef href="CDR0000045324" dictionary="Cancer.gov" audience="Patient">interferon</GlossaryTermRef> alpha. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.</ListItem></ItemizedList><Para id="_10">Bevacizumab is also being studied in the treatment of other types of cancer.</Para>                          
 </Section><Section id="_About"><Title>More About Bevacizumab</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/43234">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.39">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a607001.html">Bevacizumab </ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.40"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.41">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2023/avastin-lonsurf-improves-survival-colorectal-cancer">Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Cancer Therapies</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies">Monoclonal Antibodies</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C2039">Find Clinical Trials for Bevacizumab</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2006-10-05</DateFirstPublished><DateLastModified>2023-12-08</DateLastModified></DrugInformationSummary>
